Two former high-flying tech stocks that have been in free fall recently are Palantir (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA). Palantir's stock is down by about 37% from its high as of this writing, while Tesla shares have been more than cut in half. There are two big reasons why I'd be cautious with Palantir's stock right now: its valuation and the potential impact of reduced government spending.
Thyssenkrupp is moving ahead with a planned spin-off of a minority stake in its warship division, the group said on Friday, adding the newly created holding would be listed on the Frankfurt stock exchange. The company also said that talks with the German government about potential participation in its marine division, Thyssenkrupp Marine Systems (TKMS), were ongoing. The comments came in response to a report in Handelsblatt, which cited people familiar with the matter as saying that Thyssenkrupp had cancelled a sale of TKMS to Rheinmetall, Europe's biggest ammunition maker.
Dividend shares and high-yield funds are among the most popular investment vehicles people choose to rely on for a consistent payout or to grow their money. One of the most talked about dividend-oriented ETFs is Schwab U.S. Dividend Equity ETF (NYSE:SCHD), which tracks the Dow Jones U.S. Dividend 100 Index. SCHD is known for its focus on high-quality, dividend-paying U.S. companies, making it a go-to fund among investors seeking reliable income. But is it a smart move to allocate a considerable
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera
OK